Advanced search
Publication Cover
Emerging Microbes & Infections Volume 6, 2017 - Issue 1
Submit an article Journal homepage
750
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library

Clinical compounds that enhance pyrazinamide activity

Hongxia NiuLanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou730000, China;Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Chao MaCollege of Biological Sciences and TechnologyBeijing Forestry University, Beijing100083, China
,
Peng CuiKey Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical CollegeFudan University, Shanghai200040, China
,
Wanliang ShiDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Shuo ZhangDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Jie FengDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
David SullivanDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA
,
Bingdong ZhuLanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou730000, China
,
Wenhong ZhangKey Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical CollegeFudan University, Shanghai200040, China
&
Ying ZhangDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD21205, USA;Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical CollegeFudan University, Shanghai200040, ChinaCorrespondence[email protected]
 show all
Pages 1-3 | Received 08 Dec 2016, Accepted 14 Mar 2017, Published online: 15 Jan 2019

References

  • World Health Organization. Global tuberculosis report 2016.Geneva: WHO. Available at http://www.who.int/tb/publications/global_report/en/ (accessed 13 October 2016).
  • Zhang Y.The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45: 529–564.
  • Smith CV, Sharma V, Sacchettini JC.TB drug discovery: addressing issues of persistence and resistance. Tuberculosis 2004;84: 45–55.
  • Zhang Y, Yew WW, Barer MR.Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012;56: 2223–2230.
  • Zhang Y, Permar S, Sun Z.Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002;51: 42–49.
  • Zhang Y, Mitchison D.The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7: 6–21.
  • Zhang Y, Shi W, Zhang Wet al.Mechanisms of pyrazinamide action and resistance. Microbiol Spectr 2013;2: 1–12.
  • Chong CR, Chen X, Shi Let al.A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2: 415–416.
  • Byrne ST, Gu P, Zhou Jet al.Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51: 4495–4497.
  • Zhang Y, Wade MM, Scorpio Aet al.Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52: 790–795.
  • Byrne ST, Denkin SM, Gu Pet al.Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol 2007;56 (Pt 8): 1047–1051.
  • Byrne ST, Denkin SM, Zhang Y.Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother 2007;59: 313–316.
  • Wade MM, Zhang Y.Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2006;58: 936–941.
  • Hurdle JG, O'Neill AJ, Chopra Iet al.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Micro 2011;9: 62–75.
  • Yano T, Kassovska-Bratinova S, Teh JSet al.Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011;286: 10276–10287.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.